Background {#Sec1}
==========

Congenital cataracts (CCs) are now the most common avoidable cause of childhood blindness worldwide, accounting for 10--35% of such cases, with an estimated incidence of 0.63--9.14/10,000 births \[[@CR1]--[@CR4]\]. Management is often difficult due to the risk of amblyopia in the developing visual system and complications of glaucoma, posterior synechia or visual axis opacification, which require additional surgery \[[@CR5]\]. CCs occur due to the disruption of the lens microarchitecture or the protein function in the lens \[[@CR6]\]. Except for a very few infectious cases, only one-third of CC cases have a positive family history \[[@CR7]\], with the other two-thirds having an unknown aetiology \[[@CR8]\]. Therefore, a significant proportion are sporadic cases in which it is not known whether there is an underlying genetic cause for the lens abnormality.

Thus far, approximately 350 genes have been reported to be associated with CC (Cat-Map; <http://cat-map.wustl.edu/>); these include mutations in crystallins and gap junction, membrane transport and channel, and cytoskeletal proteins and growth and transcription factors \[[@CR9]\]. Locating and identifying the involved genes and mutations are essential to gaining an understanding of the molecular defects and pathophysiologic characteristics underlying inherited CC.

A conventional approach to identifying mutations in CC is usually performed by Sanger sequencing only in familial cases and is time-consuming and costly, with a detection rate of 30--50% in apparent autosomal dominant cases \[[@CR10], [@CR11]\]. Due to marked genetic and phenotypic heterogeneity, determining the precise genetic cause of CC and establishing a robust genotype-phenotype correlation is challenging. Next-generation DNA sequencing (NGS) is increasingly powerful as a diagnostic tool and offers speed, precision, and cost-effectiveness for heterogeneous conditions \[[@CR12]\]. This has been demonstrated in studies to determine the cause of other heterogeneous inherited eye diseases, such as congenital macular dystrophy and retinal pigmentosa \[[@CR13]--[@CR16]\]. Recent studies have also shown that NGS allows the efficient identification of genetic causes of CC in the majority of cases, thereby improving its diagnosis and clarifying inheritance patterns \[[@CR17]--[@CR19]\] while guiding genetic counselling and increasing prognostic accuracy.

In this study, we applied targeted NGS in 792 genes involved in common inherited eye diseases to detect causal mutations in a relatively large series of CCs, including a high proportion of sporadic cases, and report the different distributions of mutated genes in sporadic versus familial CC cases (sCC VS fCC), while broadening the mutation spectrum and frequency of genes responsible for CC.

Methods {#Sec2}
=======

Ethical statement {#Sec3}
-----------------

All participants (parents on behalf of their children) provided written informed consent forms for both genetic counselling and molecular genetic testing prior to enrolment. The study was approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University. All research was conducted in accordance with the Declaration of Helsinki.

Clinical evaluations and sample collection {#Sec4}
------------------------------------------

Patients who were clinically diagnosed with CC from June 2018 to May 2019 were recruited. All patients underwent a detailed ophthalmic examination, including slit-lamp examination, B ultrasound, intraocular pressure measurement, and ultrasonic A-scan, as mentioned in our previous study \[[@CR20]\]. Visual acuity (VA) was recorded in all patients who were able to cooperate. Patients diagnosed with monocular CC additionally underwent post-eyeball colour Doppler ultrasound to help in the differential diagnosis of persistent hyperplastic primary vitreous (PHPV). Children younger than 3 years old were examined under sedation with chloral hydrate. The lens phenotypes of patients and their parents were carefully recorded in all families and included childbirth history, medical history, family history and a detailed history of the gestation period, including high fever, rubella virus \[RV\] TORCHES (\[*Toxoplasma gondii*; *T*. *gondii*\], cytomegalovirus \[CMV\], herpes simplex virus \[HSV\], syphilis \[caused by *Treponema pallidum*\]), tuberculosis infection, exposure to radiation, and drug intake. Additional systemic problems were also recorded in patients and included serum biochemical tests for levels of blood glucose, calcium and phosphorous as well as urine tests. The probands for whom at least one immediate family member had a history of CC were defined as familial cases. Those who had no family history and had been excluded from infection factors were classified as sporadic cases. Blood samples were collected in children while under general anaesthesia during eye surgery and from their biological parents (Trio sequencing) in our hospital. In familial cases, blood samples of other available affected relatives were also collected.

Next-generation sequencing {#Sec5}
--------------------------

Genomic DNA was extracted from peripheral blood samples using standard methods. Panel-based NGS was performed on all subjects in this study. We designed the Target_Eye_792_V2 chip with exon-capture and untranslated regions (UTRs) of 792 genes most frequently involved in common inherited eye diseases (Additional file [1](#MOESM1){ref-type="media"}, Table S1), which were produced by BGI-Shenzhen, Guangdong, China as previously reported \[[@CR21]\]. Then, DNA fragments were sequenced by an Illumina HiSeq 2000 platform (Illumina, Inc., San Diego, CA, United States). The following databases were then used to annotate all identified variants with a minor allele frequency (MAF) \> 0.1% to eliminate benign variants as previously described \[[@CR22]\]: dbSNP1371 (<http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/snp137.txt.gz>), HapMap Project (<ftp://ftp.ncbi.nlm.nih.gov/hapmap>), 1000 Genomes Project (<ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp>), YH database (<http://yh.genomics.org.cn/>), and Exome Variant Server (<http://evs.gs.washington.edu/EVS/>). Subsequently, variant prioritization was performed to combine the total depth, quality score, MAF, potential deleterious effect and existence of mutation reports in common databases such as the Human Gene Mutation Database (HGMD), ClinVar or Online Mendelian Inheritance in Man (OMIM). Finally, variants were classified as pathogenic, likely pathogenic, uncertain significance according to the American College of Medical Genetics (ACMG) and genomics guidelines. Sanger sequencing was performed to confirm the candidate variants.

Results {#Sec6}
=======

Participant characteristics {#Sec7}
---------------------------

A total of 152 subjects of 53 families were recruited in this study, including 16 familial cases (49 subjects in total) and 37 sporadic cases (106 subjects in total). Parental samples in one familial case and six sporadic cases were not completely obtained for some reasons beyond control. All the familial cases had at least one affected parent (11 mothers and 5 fathers). In addition, the available affected immediate relatives, the brother, the paternal grandfather and the maternal grandmother in three familial cases participated in the test. The mean ages of the 53 children and their mothers and fathers were 3.0 \[1.50--6.00\], 30.72 ± 5.02, and 32.65 ± 5.19 years old, respectively. There were more binocular cases than monocular cases and more male than female cases. More detailed information is presented in Table [1](#Tab1){ref-type="table"}. No significant differences were found between sCC and fCC in the mean ages of children and the parents or other constituent ratios (*P* values are presented in Table [1](#Tab1){ref-type="table"}). Table 1Basic characteristics of the participants in our studysCCfCC*P* valueNumber of patients3716Male:female21:1610:60.623Mean age of patients3.00 (1.50--6.00)3.00 (1.63--6.75)0.133 mothers31.26 ± 4.9729.00 ± 4.880.434 fathers33.75 ± 5.3530.71 ± 4.380.324Binocular:monocular26:1115:10.067Detected cases10/37 (27.03)14/16 (87.50)**0.000**Detected variants1116Values are shown as n (%) and medians (IQRs) or medians± standard deviation for normally distributed dataBold text is used for *p* values under 0.01, indicating statistical significance

Variants identified {#Sec8}
-------------------

A total of 27 variants were found in 24 of the 53 patients with CC in our cohort, yielding a total detection rate of 45.30%. We identified variants in 10/37 (27.03%) sCC and 14/16 (87.5%) fCC cases, indicating a significant difference (*P* = 0.000, Table [1](#Tab1){ref-type="table"}). The detection rate was lower in monocular cases (4/12, 33.33%) than in binocular cases (20/41,48.80%), but the difference was not significant (*P* = 0.512).

The variants detected are presented in Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}. According to the ACMG mutation guidelines, 17 of 27 variants were classified as pathogenetic, five were likely pathogenic, and seven were uncertain significance (VUS). Table 2Detected variants in sporadic casesFamilyPhenotypeInheritance:Before/After testingGeneRefseq IDNucleotide changePredicted amino acid changeHeterozygositySegregationPathogenicityIn silico PredictionNote (other reported phenotype or references)FATHMMSIFTMutation TasterLRT1Bi, Sub, JunvenileSporadic/AR*CYP27A1*NM_000784.3c.1263 + 1G \> A--HomFather heterozygousP//D/Cerebrotendinous xanthomatosis \[[@CR23]\]2Bi,AllSporadic/new AD*CRYBB2*NM_000496.2c.487C \> Tp.Gln163\*\|p.Q163\*HetDe novo; not found in parentsP//DDNovel3Bi,AllSporadic/AD?*OPA3*NM_001017989.2c.123C \> Gp.Ile41Met\|p.I41MHetPresent in unaffected motherPresent in unaffected motherPDDDTOptic atrophy \[[@CR24]\]*JAG1*NM_000214.2c.1511A \> Gp.Asn504Ser\|p.N504SHetPBBDDAlagille syndrome \[[@CR25], [@CR26]\]4Mo,Sub + Post,Sporadic/AD or AR?*BEST1\|BEST1*NM_001139443.1\|NM_004183.3c.20G \> Ap.Ser7Asn\|p.S7NHetPresent in unaffected motherPDBDTBest vitelliform macular dystrophy \[[@CR27], [@CR28]\]5Mo, All, PHPVSporadic/AD or AR?*BEST1*NM_001139443.1\|NM_004183.3c.584C \> Tp.Ala195Val\|p.A195VHetPresent in unaffected fatherPDDDDBestrophinopathy \[[@CR29], [@CR30]\]6Bi,NucSporadic/X-linked?*NHS*NM_001291867.1c.2774_2775dupp.Gln926Leufs\*3Hemi/HetPresent in unaffected motherLP////Novel7Bi,OD-Dot,OS-Ant+DotSporadic/X-linked?*NHS*NM_001291867.1c.2933 T \> Cp.Ile978Thr\|p.I978THet/HemiPresent in unaffected fatherVUSBBDDNovel8Mo,Sub, JunvenileSporadic/AR?*WFS1*NM_006005.3c.2603G \> Ap.Arg868HisHetPresent in unaffected fatherLPDDDDWolfram-like syndrome \[[@CR31]--[@CR33]\]9Mo,NucSporadic/XR*COL4A5*NM_033380.2c.4003C \> Tp.Pro1335Ser\|p.P1335SHemi/HetYes/Present in son and unaffected motherVUSDDDDAlport Syndrome \[[@CR34]\]10Bi,Cort+Sub,FEVR, Cleft Lip and PalateSporadic/AD?*TSPAN12*NM_012338.3c.194C \> Tp.Pro65Leu\|p.P65LHetPresent in unaffected fatherVUSBBDDNovel, gene associated with FEVR \[[@CR35]\]*Bi* binocular, *Mo* monocular, *Sub* subcapsular, *Cort* cortical, *Post* posterior polar, *Nuc* nuclear, *Ant* anterior polar, *All* all white, *Dot* dot-like, *Peri* perinuclear, *Micro* microphthalmia, *Hom* homozygosis, *Het* heterozygosis, *P* pathogenic, *LP* likely pathogenic, *VUS* variant of unknown significance, *D* damaging, *B* benign, *T* toleratedTable 3Detected variants in familial casesFamily IDPhenotypeInheritance Before/After testingGeneRefseq IDNucleotide changePredicted amino acid changeHeterozygositySegregationPathogenicityIn silico predictionNoteFATHMMSIFTMutation TasterLRT1Bi,AllAD/AD*CRYGC*NM_020989.3c.497C \> Tp.Ser166Phe\|p.S166FHetYes/present in affected motherPDDDD\[[@CR19]\]2Bi,LamAD/AD*CRYGD*NM_006891.3c.70C \> Ap.Pro24Thr\|p.P24THetYes/present in affected fatherPBB//\[[@CR36], [@CR37]\]3Bi, OS-All; OD-DotAD/X-linked*BCOR*NM_001123385.1c.3490C \> Tp.Arg1164\*\|p.R1164\*HetYes/present in affected motherP//D/OFCD \[[@CR38]\]4Bi, NuAD/AD*CRYAA*NM_000394.3c.61C \> Tp.Arg21Trp\|p.R21WHetYes/present in affected motherPDDDD\[[@CR37], [@CR39]\]5Bi,CoraAD/AD*CRYGD*NM_006891.3c.70C \> Ap.Pro24Thr\|p.P24THetYes/present in affected motherPBB//\[[@CR36], [@CR37]\]6Bi, NuAD/AD*BMP4*NM_001202.4c.751C \> Tp.His251Tyr\|p.H251YHetNK/present in unaffected motherPBDDDMicrophthalmia \[[@CR40]\]*CRYBA1*NM_005208.4c.626C \> Gp.Ser209Trp\|p.S209WHetYes/present in affected father and paternal grandfatherPDDDD\[[@CR17]\]7Bi,AllAD/AD*CRYGC*NM_020989.3c.192delp.Asp65Thrfs38\|p.D65Tfs38HetYes/present in affected mother and elder brotherP////Adjacent loci c.193del \[[@CR41]\]8Bi,Peri+CorAD/?AD or AR*OPA3*NM_001017989.2c.123C \> Gp.Ile41Met\|p.I41MHetYes/present in affected motherLPDDDTOptic atrophy \[[@CR24]\]9Bi+MicroAD/AD*GJA8*NM_005267.4c.136G \> Ap.Gly46Arg\|p.G46RHetYes, present in affected fatherLPDDDD\[[@CR42]\]10Bi+DotAD/AD*PAX6*NM_001310158.1c.52G \> Ap.Gly18ArgHetYes, present in affected motherLPDDDTPeter's \[[@CR43]\]11Bi AllAD/AD*PAX6*NM_001310158.1c.113G \> Cp.Arg38Pro\|p.R38PHetYes/presented in affected mother from a consanguineous familyVUSDDDTc.113G \> A (p.R38Q) CC and nystagmus (HGMD)12Bi,Nys,Post +OD-ASDAD/AD*PAX6*NM_001310158.1c.966delp.Phe323Serfs56\|p.F323Sfs56HetNK/parental samples unavailable, mother affectedP////Aniridia \[[@CR44]\]13Bi,Post+SubAD*CYP1B1*NM_000104.3c.319C \> Gp.Leu107Val\|p.L107VHom/hetPresent in affected father and unaffected motherVUS//DDGlaucoma \[[@CR45]\]*FBN1*NM_000138.4c.7559C \> Tp.Thr2520Met\|p.T2520MHetPresent in affected fatherVUSDBDDMarfan \[[@CR46]\]14BiAD/AD*WFS1*NM_006005.3c.449C \> Tp.Ala150Val\|p.A150VHetPresent in affected motherVUSDBDDWolfman-like syndrome \[[@CR31]--[@CR33]\]*Bi* binocular, *All* all white, *Lam* lamellar, *Sub* subcapsular, *Cort* cortical, *Post* posterior polar, *Nuc* nuclear, *ASD* anterior segment dysplasia, *Dot* dot-like, *Peri* perinuclear, *Micro* microphthalmia, *Cora* coralliform, *Nys* nystagmus, *Hom* homozygosis, *Het* heterozygosis, *P* pathogenic, *LP* likely pathogenic, *VUS* variant of unknown significance, *D* damaging, *B* benign, *T* tolerated, *NK* not known, *OFCD* Oculofaciocardiodental syndrome

We identified three novel likely cataractous causative mutations in sCC in *CRYBB2* and *NHS (\*2)*, one of which was a de novo mutation in *CRYBB2* c.487C \> T (p. Gln163\*\|p. Q163\*). Eight of the 27 variants detected in our cohort were previously reported pathogenic gene mutations in CC, including loci in *CRYGC*, *CRYGD(\*2)*, *CRYAA*, *CRYBA1*, and *GJA8* and adjacent loci in *CRYGC* and *PAX6*. Another 16 variants involved in additional ocular or systemic diseases that had been reported or included by HGMD or ClinVar were also identified, including *CYP27A1*, *OPA3*, *JAG1*, *BEST1*, *BMP4, CYP1B1*, and *TSPAN12* (see Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, Note column).

In terms of gene function, genes encoding crystallins were the most frequently identified in our cohort, accounting for 7/27 (25.93%) of the cases, followed by cytoskeletal proteins (18.52%), X-linked syndromic proteins (14.81%) and transcriptional factors (11.11%).

Differential distribution of mutational genes {#Sec9}
---------------------------------------------

A comparison of the distributions of mutational genes between fCC and sCC showed that variants in crystallins accounted for the highest proportion (37.50%) in fCC cases but only 9.00% in sCC cases (Fig. [1](#Fig1){ref-type="fig"}). The sporadic cases mainly consisted of X-linked syndromic proteins and structural protein genes, including transmembrane and collagen-associated proteins. Fig. 1Different distributions of mutational genes in familial versus sporadic congenital cataracts

Discussion {#Sec10}
==========

Approximately 70% of CC cases may occur alone, and 15% of such cases may be accompanied by other ocular abnormalities, such as microphthalmia, aniridia, or retinal degeneration. In another 15% of cases, cataracts are one part of a multisystem genetic disorder \[[@CR47]\]. To obtain clues related to the noncataractous phenotype, we designed a panel with exon-capture and NGS targeting of the 792 genes most frequently involved in common inherited eye diseases. Compared to related previous studies, our study included the largest numbers of patients and targeted genes. We achieved detection rates in familial and sporadic cases similar to those in a recent study \[[@CR37]\]. Although the overall detection rate (45.3%) in our cohort was apparently lower than that in the other studies listed in Table [4](#Tab4){ref-type="table"}, these rates are not comparable due to differences in the proportions of participants. Most of the studies \[[@CR17]--[@CR19]\] included only binocular cataracts, whereas we enrolled many monocular cases. Regarding the distribution of genes, our result was slightly different from those reported previously. Li et al. \[[@CR37]\] reported that variants in the crystallin genes were the most frequent mutations found in their study, whether in familial or sporadic cases. We found that variants in crystallins accounted for a similar proportion of fCC cases but only 1 sCC case (Fig. [1](#Fig1){ref-type="fig"}). X-linked syndromic proteins and structural protein genes, such as transmembrane and collagen-associated proteins, accounted for most of the sCCs in our study. Table. 4Studies related to the mutation spectrum of CC obtained using NGS in the past 5 yearsOur cohortLi et al., 2018 \[[@CR37]\]Gillespie et al., 2014 \[[@CR17]\]Ma et al., 2016 \[[@CR19]\]Zhai et al., 2017 \[[@CR18]\]Target genes792 inherited eye diseases80 cataract-associated genes115 genes associated with CC32 cataract -associated genes54 cataract-associated genesDetection rateFamilial, 87.5% sporadic, 27.03%familial, 75% sporadic, 47.8%70%70%62.96%Participants38 sporadic and 16 familial cases, 42 bilateral and 12 unilateral23 sporadic and 16 familial cases, all bilateral15 sporadic and 21 familial cases all bilateral 16 syndromic24 sporadic and 22 familial cases all bilateral nonsyndromic25 familial and 2 sporadic

In our study, approximately 17/27 (62.96%) variants provided clues regarding the possibility of complication with inherited ocular or systemic diseases other than CC. Among these, nine identified loci provided additional ophthalmological diagnostic information. For instance, *OPA3* mutations are associated with optic atrophy \[[@CR24]\], *BEST1* mutations are associated with best vitelliform macular dystrophy (BEST) \[[@CR27]--[@CR30]\], *TSPAN12* mutations are associated with familial exudative vitreoretinopathy (FEVR) \[[@CR35]\], *PAX6* mutation are associated with aniridia and Peter's anomaly \[[@CR48]\], and *CYP1B1* mutations are associated with glaucoma \[[@CR45]\]. In addition, we also identified a monoallelic mutation in *BMP4*, which has been mostly associated with microphthalmia \[[@CR40]\] or facial clefts \[[@CR49]\]. Eight variants were associated with systemic syndrome. *WFS1* is the most common causative gene in Wolfram-like syndrome, a rare autosomal dominant disease characterized by congenital progressive hearing loss, diabetes mellitus, and optic atrophy \[[@CR50]\]. *COL4A5* is one of the causative genes in Alport Syndrome, a genetic condition characterized by progressive loss of kidney function, hearing, and eye abnormalities, including misshapen lenses and abnormal retina \[[@CR34]\]. *JAG1* has been associated with Alagille syndrome, which involves cholestasis, cardiac defects, ocular abnormalities, skeletal abnormalities and characteristic faces. Loss-of-function mutations in the *BCOR* gene have been identified in individuals with oculo-facio-cardio-dental syndrome (OFCD), which includes microcornea, CC, and facial, cardiac, and dental abnormalities \[[@CR38]\]. Mutations in the *FBN1* (fibrillin-1) gene may be diagnostic of Marfan syndrome \[[@CR46]\]. *NHS* mutations have been identified in patients with Nance-Horan syndrome (NHS), an X-linked developmental disorder characterized by CC, dental anomalies, facial dysmorphism and, in some cases, mental retardation \[[@CR51]\]. Clinically, a new diagnosis was made after surgery and with reference to genetic testing in at least two patients in our cohort. One of the sporadic cases (ID 10 in Table [2](#Tab2){ref-type="table"}) presented some retinal abnormalities during operations after the removal of cataracts in both eyes, including settled subretinal exudates and dragging of the optic disc. Combined with this clinical manifestation, we have clarified the diagnosis of FEVR with regard for the *TSPAN12* mutation, which is a pathogenic gene known to indicate FEVR. We also observed dental, facial and mental anomalies and made a new diagnosis of NHS at 2 years after the first CC operation was performed in one of the sporadic cases with an identified *NHS* mutation (ID 6 in Table [2](#Tab2){ref-type="table"}). However, whether other variants are associated with a noncataractous phenotype is difficult to confirm. For example, in family 3 (Table [2](#Tab2){ref-type="table"}), we cannot clearly ascribe one of these variants, *OPA3* or *JAG1* to a cataractogenic effect. It is possible that one or more gene mutations cause multiple eye abnormalities at the same time, and cataracts are only one of the first manifestations found in the clinic. During the follow-up period after cataract surgery, we will pay more attention to whether the child tends to experience optic atrophy and will give suggestions for monitoring liver and cardiac function. The relationships between complicated phenotypes and mutations in ocular genes are not explicit. Thus, more cases should be included, and more experiments should be performed to verify these connections.

It is worth emphasizing that those identified variants in non-classical cataract genes may not be initially ascribed to a cataractogenic effect. They might indicate other inherited eye disorders or syndromes, in which a cataractous phenotype may not be presented in every carrier. Another possibility was that the exact cataractous causative genes are located in regions that have not yet been detected, or even that the cataractous phenotype was not caused by genetic factors at all or may involve epigenetic factors.

The phenomenon in which identified heterozygous variants are also present in unaffected parents in sporadic cases (Table [2](#Tab2){ref-type="table"}) might be explained by incomplete and variable penetrance; the underlying mechanisms of this phenomenon remain largely unknown. A recent study also provides support showing that variants associated with inherited eye disorders are frequently encountered in unaffected individuals and that one in six genes implicated in inherited eye disorders are potentially associated with variable penetrance \[[@CR52]\]. The number of variants and genes that do not segregate (Table [2](#Tab2){ref-type="table"}) is relatively high in our study. Some of these genes, such as *BEST1* and *WFS1*, were shown to exhibit variable penetrance in a previous study \[[@CR50]\]. Incomplete penetrance of the remaining genes might not be supported by sufficient evidence, or these genes might not be the causative genes. This phenomenon might also be due to the limited number of samples detected. In a future study, we will continue to expand the sample size, collect more samples of family members, and improve the history tracking. We believe that the proportion of this phenomenon will be significantly reduced.

This study emphasizes the power and necessity for trio NGS analyses of CC families. By identifying pathogenic heterozygous and homozygous mutations, de novo mutations, and parental mosaicism, such analyses may reveal a new pattern of inheritance in CC with significance not limited to the affected child. However, trio NGS can reveal numerous VUS, for which functional validation is mandatory, although it is still a challenge. Furthermore, future research is required to determine the clinical significance of non-Mendelian inheritance, the intricate mutual effect between genetic predispositions and environmental factors, and interactions between genetic and epigenetic. These studies will provide important insights into the pathogenesis and the complex genotype-to-phenotype association of CC. In the future, these results may also lead to the development of novel gene therapies for some types of congenital cataracts, similar to other inherited eye diseases.

A limitation of this study is that samples in which no mutations were identified could be further submitted to whole-genome sequencing but rarely are because it is challenging to obtain a sufficient amount of blood from infants and young children to meet experimental needs.

Conclusions {#Sec11}
===========

In conclusion, our study highlights the benefits of an NGS approach combined with the analysis of a large targeted group of genes in a setting of genetically heterogeneous CC patients. Our findings provide significant diagnostic information and enable more accurate genetic counselling. Our results expand what we know about the mutation spectrum and frequencies of genes responsible for CC as well as the different distributions of genes mutated in familial and sporadic cases in the Chinese population.
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**Additional file 1:** **Table S1.** Gene list of capture panel. 792 genes most frequently involved in common inherited eye diseases.

CC

:   Congenital cataract

sCC

:   Sporadic congenital cataract

fCC

:   Familial congenital cataract
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:   Next-generation DNA sequencing
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:   Human Gene Mutation Database
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:   American College of Medical Genetics

VUS

:   Uncertain significance

FEVR

:   Familial exudative vitreoretinopathy

BEST

:   Best vitelliform macular dystrophy

NHS

:   Nance-Horan syndrome
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